Anti-folate receptor 1 antibodies and uses thereof
An antibody, monoclonal antibody technology, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, anti-tumor drugs, etc., can solve the problem of low expression level
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0242] The invention provides the following non-limiting embodiments.
Embodiment approach 1
[0243] Embodiment 1 is an isolated monoclonal antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3, which has the following Peptide sequence:
[0244] a. SEQ ID NO: 38, 39, 40, 62, 63 and 64, respectively;
[0245] b. SEQ ID NO: 17, 18, 19, 41, 42 and 43, respectively;
[0246] c. SEQ ID NO: 20, 21, 22, 44, 45 and 46, respectively;
[0247] d. SEQ ID NO: 23, 24, 25, 47, 48 and 49, respectively;
[0248] e. SEQ ID NO: 26, 27, 28, 50, 51 and 52, respectively;
[0249] f. SEQ ID NO: 29, 30, 31, 53, 54 and 55, respectively;
[0250]g. SEQ ID NO: 32, 33, 34, 56, 57 and 58, respectively; or
[0251] h. SEQ ID NO: 35, 36, 37, 59, 60 and 61, respectively;
[0252] Wherein the antibody or antigen-binding fragment thereof specifically binds to FOLR1, preferably human FOLR1.
Embodiment approach 2
[0253] Embodiment 2 is an isolated monoclonal antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3, which has the following Peptide sequence:
[0254] a. SEQ ID NO: 86, 87, 88, 110, 111 and 112, respectively;
[0255] b. SEQ ID NO: 65, 66, 67, 89, 90 and 91, respectively;
[0256] c. SEQ ID NO: 68, 69, 70, 92, 93 and 94, respectively;
[0257] d. SEQ ID NO: 71, 72, 73, 95, 96 and 97, respectively;
[0258] e. SEQ ID NO: 74, 75, 76, 98, 99 and 100, respectively;
[0259] f. SEQ ID NO: 77, 78, 79, 101, 102 and 103, respectively;
[0260] g. SEQ ID NO: 80, 81, 82, 104, 105 and 106, respectively; or
[0261] h. SEQ ID NO: 83, 84, 85, 107, 108 and 109, respectively;
[0262] Wherein the antibody or antigen-binding fragment thereof specifically binds to FOLR1, preferably human FOLR1.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


